Pro Medicus Limited (ASX: PME) has entered a $33 million, nine-year agreement with the University of Kentucky College of Medicine. The deal involves implementing the company’s cloud-based Visage 7 Enterprise Imaging Platform across the university's healthcare affiliates, including two major hospitals. This initiative aims to enhance diagnostic imaging capabilities.
Pro Medicus CEO Sam Hupert highlighted the University of Kentucky's addition to a "growing list of academic clients," underscoring the platform's expanding adoption in the healthcare sector. The contract solidifies Pro Medicus' position as a leader in medical imaging software.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 20, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.